It appears that miR-93 is able to affect a number of factors such as programmed cell death 1 ligand 2 (PDCD1LG2) associated with cancer immunotherapy, G-protein coupled receptor 137C (GPR137C) and mitogen-activated protein kinase 2 (MAPK2). The gene discussed is PDCD1LG2; the disease is cancer.